Literature DB >> 9245615

Preparation and maintenance of SCID-hu mice for HIV research.

G C Bristol1, L Y Gao, J A Zack.   

Abstract

The SCID-hu mouse bearing a functional human thymic implant can be easily infected with HIV. Infection results in virus replication and relatively rapid depletion of CD4+ human thymocytes, resulting in a pathologic profile similar to that seen in the thymus of HIV-infected humans. The use of the SCID-hu model for HIV research requires protection of the animals from opportunistic infections and protection of the operators from human pathogens. This discussion describes reliable methods of animal care and surgical procedures to meet these needs.

Entities:  

Mesh：

Year:  1997        PMID： 9245615     DOI： 10.1006/meth.1997.0488

Source DB:  PubMed          Journal:  Methods        ISSN： 1046-2023            Impact factor:   3.608


  8 in total

1.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Using the BLT humanized mouse as a stem cell based gene therapy tumor model.

Authors:  Dimitrios N Vatakis; Gregory C Bristol; Sohn G Kim; Bernard Levin; Wei Liu; Caius G Radu; Scott G Kitchen; Jerome A Zack
Journal:  J Vis Exp       Date:  2012-12-18       Impact factor: 1.355

3.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Authors:  Dimitrios N Vatakis; Richard C Koya; Christopher C Nixon; Liu Wei; Sohn G Kim; Patricia Avancena; Gregory Bristol; David Baltimore; Donald B Kohn; Antoni Ribas; Caius G Radu; Zoran Galic; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

4.  Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Authors:  Scott G Kitchen; Michael Bennett; Zoran Galić; Joanne Kim; Qing Xu; Alan Young; Alexis Lieberman; Aviva Joseph; Harris Goldstein; Hwee Ng; Otto Yang; Jerome A Zack
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

Review 5.  Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

6.  In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.

Authors:  Matthew D Marsden; Brian A Loy; Xiaomeng Wu; Christina M Ramirez; Adam J Schrier; Danielle Murray; Akira Shimizu; Steven M Ryckbosch; Katherine E Near; Tae-Wook Chun; Paul A Wender; Jerome A Zack
Journal:  PLoS Pathog       Date:  2017-09-21       Impact factor: 6.823

7.  Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.

Authors:  Matthew D Marsden; Tian-Hao Zhang; Yushen Du; Melanie Dimapasoc; Mohamed S A Soliman; Xiaomeng Wu; Jocelyn T Kim; Akira Shimizu; Adam Schrier; Paul A Wender; Ren Sun; Jerome A Zack
Journal:  Cell Rep Med       Date:  2020-12-22

8.  Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo.

Authors:  Lars Pache; Matthew D Marsden; Peter Teriete; Alex J Portillo; Dominik Heimann; Jocelyn T Kim; Mohamed S A Soliman; Melanie Dimapasoc; Camille Carmona; Maria Celeridad; Adam M Spivak; Vicente Planelles; Nicholas D P Cosford; Jerome A Zack; Sumit K Chanda
Journal:  Cell Rep Med       Date:  2020-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.